Full Press Release Details
Anticipates Fifth Consecutive Quarter of Sequential Double Digit Growth;
132% Increase in CGuard EPS Sales for the First Quarter of 2018;
Total Quarterly Company Sales to Exceed $1 Million
Aviv, Israel- April 3, 2018 - InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus
management technologies and neurovascular devices, today announced preliminary unaudited sales results for the first quarter of
for the fiscal first quarter of 2018 as compared to the fiscal first quarter of 2017(1):
Barry, PhD, Chief Executive Officer of InspireMD, commented, "We continue to effectively execute against our commercial
plan, as evidenced by the fact that we achieved an expected 130% year-over-year increase in sales of CGuard EPS, as well
as our 5th consecutive quarter of sequential double-digit growth with over $1 million in total sales for the quarter.
Not only did we generate strong year-over-year growth, but we achieved an expected 37% sequential growth in sales of CGuard
EPS for the first quarter of 2018. We are successfully implementing our new commercial strategy and, consistent with this strategy,
we continue to see rapid uptake among key opinion leaders and CGuardTM EPS continues to be prominently featured at
leading industry conferences."
Actual results may differ materially from the estimates described above due to developments or other information that may arise
between now and the time the financial results for the first quarter of 2018 are finalized. These preliminary results should not
be viewed as a substitute for our first quarter reviewed consolidated financial statements prepared in accordance with GAAP.
seeks to utilize its proprietary MicroNet technology to make its products the industry standard for embolic protection
and to provide a superior solution to the key clinical issues of current stenting in patients with a high risk of distal embolization,
no reflow and major adverse cardiac events.
intends to pursue applications of this MicroNet technology in coronary, carotid (CGuard ), neurovascular, and peripheral
artery procedures. InspireMD's common stock is quoted on the NYSE American under the ticker symbol NSPR and certain warrants
are quoted on the NYSE American under the ticker symbol NSPR.WS.
press release contains "forward-looking statements." Such statements may be preceded by the words "intends,"
"may," "will," "plans," "expects," "anticipates," "projects,"
"predicts," "estimates," "aims," "believes," "hopes," "potential"
or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are
subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot
be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking
statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance
of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability
to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much
larger, multinational companies, (v) product liability claims, (vi) product malfunctions, (vii) our limited manufacturing capabilities
and reliance on subcontractors for assistance, (viii) insufficient or inadequate reimbursement by governmental and other third
party payers for our products, (ix) our efforts to successfully obtain and maintain intellectual property protection covering
our products, which may not be successful, (x) legislative or regulatory reform of the healthcare system in both the U.S. and
foreign jurisdictions, (xi) our reliance on single suppliers for certain product components, (xii) the fact that we will need
to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive
or difficult to obtain and (xiii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign
currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws
and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors
that may affect the realization of forward looking statements is set forth in the Company's filings with the Securities
and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q.
Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov.
The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information,
future events or otherwise.